Target Price | $142.59 |
Price | $133.57 |
Potential |
6.75%
register free of charge
|
Number of Estimates | 22 |
22 Analysts have issued a price target Abbott Laboratories 2026 .
The average Abbott Laboratories target price is $142.59.
This is
6.75%
register free of charge
$159.00
19.04%
register free of charge
$127.00
4.92%
register free of charge
|
|
A rating was issued by 30 analysts: 18 Analysts recommend Abbott Laboratories to buy, 11 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Abbott Laboratories stock has an average upside potential 2026 of
6.75%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion $ | 41.95 | 44.65 |
4.59% | 6.43% | |
EBITDA Margin | 21.15% | 26.81% |
2.37% | 26.78% | |
Net Margin | 31.95% | 15.72% |
123.90% | 50.79% |
24 Analysts have issued a sales forecast Abbott Laboratories 2025 . The average Abbott Laboratories sales estimate is
This results in the following potential growth metrics:
13 Analysts have issued an Abbott Laboratories EBITDA forecast 2025. The average Abbott Laboratories EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
12 Abbott Laboratories Analysts have issued a net profit forecast 2025. The average Abbott Laboratories net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 7.67 | 4.03 |
134.56% | 47.46% | |
P/E | 33.10 | |
EV/Sales | 5.35 |
12 Analysts have issued a Abbott Laboratories forecast for earnings per share. The average Abbott Laboratories EPS is
This results in the following potential growth metrics and future valuations:
Abbott Laboratories...
Analyst | Rating | Action | Date |
---|---|---|---|
Wells Fargo |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
Raymond James |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
Barclays |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
Morgan Stanley |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
RBC Capital |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
Stifel |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
Analyst Rating | Date |
---|---|
Locked
Wells Fargo:
Locked
➜
Locked
|
Apr 17 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Apr 17 2025 |
Locked
Raymond James:
Locked
➜
Locked
|
Apr 17 2025 |
Locked
Barclays:
Locked
➜
Locked
|
Apr 17 2025 |
Locked
Morgan Stanley:
Locked
➜
Locked
|
Apr 17 2025 |
Locked
RBC Capital:
Locked
➜
Locked
|
Apr 17 2025 |
Locked
Stifel:
Locked
➜
Locked
|
Apr 17 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.